gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Kallikrein-related peptidase 14

KLK14, hK14, kallikrein 14, Kallikrein-related peptidase 14
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. An additional transcript variant has been described but its full length nature has not been determined. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Kallikrein, KLK6, KLK5, Trypsin, HNP
Papers on KLK14
mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.
Scorilas et al., In Clin Chem Lab Med, Mar 2016
Based on our preliminary results regarding the differential mRNA expression of several KLK genes in peripheral blood mononuclear cells (PBMCs) of patients with chronic lymphocytic leukemia (CLL) compared to healthy blood donors, we decided to study the diagnostic and prognostic potential of KLK14 mRNA expression in CLL.
Rhododenol-induced leukoderma in a mouse model mimicking Japanese skin.
Suzuki et al., Yamagata, Japan. In J Dermatol Sci, Jan 2016
METHODS: Hairless hk14-SCF Tg mice with melanocytes distributed in the epidermis were used for this study.
KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Hovnanian et al., Paris, France. In Plos Genet, Sep 2015
Specifically, using in situ zymography and specific protease substrates, we showed that Klk5 knockout reduced epidermal proteolytic activity, particularly its downstream targets proteases KLK7, KLK14 and ELA2.
Expression and bioregulation of the kallikrein-related peptidases family in the human neutrophil.
Figueroa et al., Valdivia, Chile. In Innate Immun, Aug 2015
RT-PCR showed that blood neutrophils expressed only KLK1, KLK4, KLK10, KLK13, KLK14 and KLK15 mRNAs, whereas the non-differentiated HL-60 cells expressed most of them, with exception of KLK3 and KLK7.
Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition.
Harris et al., Brisbane, Australia. In Biochem J, Aug 2015
These findings provide new insights into protease inhibitor function and design that we apply by engineering novel inhibitors for classical serine proteases, trypsin and chymotrypsin and two kallikrein-related peptidases (KLK5 and KLK14) that are implicated in various cancers and skin diseases.
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Reboud-Ravaux et al., Paris, France. In J Med Chem, Feb 2015
The inhibition of kallikreins 5 and 7, and possibly kallikrein 14 and matriptase, (that initiates the kallikrein proteolytic cascade) constitutes an innovative way to treat some skin diseases such as Netherton syndrome.
Kallikreins are involved in an miRNA network that contributes to prostate cancer progression.
Yousef et al., In Biol Chem, 2014
Target prediction identified 23 miRNAs that are dysregulated between high and low risk biochemical failure and are predicted to target five kallikreins linked to prostate cancer; KLK2, KLK3, KLK4, KLK14 and KLK15.
Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer.
Darmoul et al., In Biol Chem, 2014
We recently reported the ectopic expression of KLK4 and KLK14 in colonic cancers and their signaling to control cell proliferation.
Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
Meyer-Hoffert et al., Kiel, Germany. In J Invest Dermatol, 2014
Recombinant Spink6 efficiently inhibited mouse Klk5 and human KLK2, KLK4, KLK5, KLK6, KLK7, KLK12, KLK13, and KLK14, whereas human KLK1 and KLK8 were not inhibited.
Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Hovnanian et al., Paris, France. In J Exp Med, 2014
Transgene expression resulted in increased proteolytic activity attributable to KLK5 and its downstream targets KLK7, KLK14, and ELA2.
Induction of complement C3a receptor responses by kallikrein-related peptidase 14.
Lambris et al., Philadelphia, United States. In J Immunol, 2013
Indeed, KLKs exemplified by KLK14 were efficiently able to cleave C3, the point of convergence of the complement cascade, indicating a potential modulation of C3-mediated functions.
1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.
El Amri et al., Paris, France. In Bioorg Med Chem Lett, 2013
We describe here 1,2,4-triazoles derivatives identified as transient inactivators acting at the nanomolar level on human kallikreins (hK5, hK7 and hK14) and matriptase.
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.
Villoutreix et al., Paris, France. In Eur J Med Chem, 2012
The efficacy and mechanism of inhibition of the identified new families of organic compounds were analyzed not only for hK5 but also on other proteases implicated in the cascades (hK7, hK14 and matriptase).
The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness.
Australian Prostate Cancer BioResource et al., Brisbane, Australia. In Biol Chem, 2012
genetic variants in the KLK14 locus are associated with risk and/or aggressiveness of prostate cancer
Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors.
Darmoul et al., Calgary, Canada. In Biol Chem, 2012
KLK14, acting via PAR-2, represents an autocrine/paracrine regulator of colon tumorigenesis
Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14.
Hollenberg et al., Calgary, Canada. In Biol Chem, 2012
KLK8 and KLK14 can signal differentially via the PARs to affect tissue function
Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues.
Scorilas et al., Athens, Greece. In Thromb Haemost, 2011
KLK14 gene expression could be evaluated as a putative independent diagnostic biomarker in breast tumour biopsies.
Human kallikrein 14 (KLK14) expression in salivary gland tumors.
Darling et al., London, Canada. In Int J Biol Markers, 2010
The differences in the levels of KLK14 suggest that KLKs may aid in the differential diagnosis of salivary gland tumors. The coexpression of KLKs suggests their possible involvement in an enzymatic pathway activated in salivary gland.
Human tissue kallikrein gene family: applications in cancer.
Diamandis et al., Toronto, Canada. In Cancer Lett, 2005
For example, hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13 and hK14 are emerging biomarkers for ovarian, breast, prostate and testicular cancer.
Human tissue kallikreins and testicular cancer.
Diamandis et al., Toronto, Canada. In Apmis, 2003
In testicular germ cell tumors, some tissue kallikrein genes, including KLK5, KLK10, KLK13 and KLK14, were found to be significantly down-regulated.
share on facebooktweetadd +1mail to friends